Document is current
Any future updates will be listed below
-
Authors
Tomlins, Scott A. https://orcid.org/0000-0001-8661-9821
Khazanov, Nickolay A.
Bulen, Benjamin J.
Hovelson, Daniel H.
Shreve, Melissa J. https://orcid.org/0000-0002-5983-4216
Lamb, Laura E.
Matrana, Marc R.
Burkard, Mark E.
Yang, Eddy Shih-Hsin
Edenfield, William Jeffery
Dees, E. Claire
Onitilo, Adedayo A.
Thompson, Michael https://orcid.org/0000-0001-7930-4610
Buchschacher, Gary L. Jr
Miller, Alan M.
Menter, Alexander
Parsons, Benjamin
Wassenaar, Timothy
Hwang, Leon C.
Suga, J. Marie
Siegel, Robert
Irvin, William Jr
Nair, Suresh
Slim, Jennifer N.
Misleh, Jamal
Khatri, Jamil
Masters, Gregory
Thomas, Sachdev
Safa, Malek
Anderson, Daniel M.
Kwiatkowski, Kat
Mitchell, Khalis https://orcid.org/0000-0001-8742-4727
Hu-Seliger, Tina
Drewery, Stephanie
Fischer, Andrew
Plouffe, Komal
Czuprenski, Eric
Hipp, Jennifer
Reeder, Travis
Vakil, Hana
Johnson, D. Bryan
Rhodes, Daniel R.
- License Information
-
More Information
Article History
Received: 25 January 2022
Accepted: 12 January 2023
First Online: 7 February 2023
Competing interests
: Khazanov, Shreve, Lamb, Hovelson, Kwiatkowski, Mitchell, Hu-Seliger, Stephanie Drewery, Fischer, Hipp, Reeder, Vakil, Bulen, Johnson, Rhodes and Tomlins are/were equity holders and/or employees of Strata Oncology. Drs. Tomlins, Rhodes, Khazanov, and Johnson are named as co-inventors on a pending patent to Strata Oncology related to the IRS model described herein. Dr. Tomlins and Rhodes are equity holders in Javelin Oncology. Dr. Tomlins previously served as a consultant to Strata Oncology and has consulted for Astellas/Medivation and Janssen. He has received research (to University of Michigan) funding from Astellas and has received travel support from the Prostate Cancer Foundation. Dr. Burkard reports receiving research funding from Abbvie, Genentech, Puma Biotechnology, Arcus Biosciences, Apollomics, and Loxo Oncology. Dr. Matrana reports receiving fees for serving on the speaker’s bureau from Pfizer, Janssen, Astellas, AstraZeneca Eisai Pharmaceuticals, Bristol-Myers Squibb, Genentech, SirTex, Merck and as a consultant from AstraZeneca. Dr. Yang reports receiving fees for serving on the advisory board from AstraZeneca, Bayer, Clovis Oncology, and for receiving research support from Eli Lilly and Puma Biotechnology. Dr. Parsons reports receiving fees for serving on the speaker’s bureau and advisory board from Amgen and Celgene, and for research funding from the Wisconsin Idea Grant, Gundersen Medical Foundation. Dr. Thompson reports receiving consulting fees from Syapse Precision Medicine Council, Elsevier ClinicalPath, Adaptive, UpToDate, GlaxoSmithKline, Takeda, Celgene, Doximity, and institutional research funding from Abbvie, Bristol-Myers Squibb, CRAB CTC, Denovo, Hoosier Research Network, Eli Lilly, LynxBio, Takeda, and TG Therapeutics. Drs. Dees, Burkard, Matrana, and Yang received fees for serving on the Strata Oncology Clinical Advisory Board. Dr. Thompson reports receiving fees for Ad Boards with Sanofi. Dr. Thompson reports a recent affiliation with Tempus Labs (Chicago, IL). The remaining authors declare no competing interests.
